A systematic review and meta-analysis of gene therapy in animal models of cerebral glioma:why did promise not translate to human therapy?

Autor: Hirst, T. C., Vesterinen, H. M., Conlin, S., Egan, K. J., Antonic, A., Lawson Mclean, A., Macleod, M. R., Grant, R., Brennan, P. M., Sena, E. S., Whittle, I. R.
Jazyk: angličtina
Rok vydání: 2014
Zdroj: Hirst, T C, Vesterinen, H M, Conlin, S, Egan, K J, Antonic, A, Lawson Mclean, A, Macleod, M R, Grant, R, Brennan, P M, Sena, E S & Whittle, I R 2014, ' A systematic review and meta-analysis of gene therapy in animal models of cerebral glioma : why did promise not translate to human therapy? ', Evidence-based Preclinical Medicine, vol. 1, no. 1, pp. 21-33 . https://doi.org/10.1002/ebm2.6
DOI: 10.1002/ebm2.6
Popis: BackgroundThe development of therapeutics is often characterized by promising animal research that fails to translate into clinical efficacy; this holds for the development of gene therapy in glioma. We tested the hypothesis that this is because of limitations in the internal and external validity of studies reporting the use of gene therapy in experimental glioma.MethodWe systematically identified studies testing gene therapy in rodent glioma models by searching three online databases. The number of animals treated and median survival were extracted and studies graded using a quality checklist. We calculated median survival ratios and used random effects meta-analysis to estimate efficacy. We explored effects of study design and quality and searched for evidence of publication bias.ResultsWe identified 193 publications using gene therapy in experimental glioma, including 6,366 animals. Overall, gene therapy improved median survival by a factor of 1.60 (95% CI 1.53–1.67). Study quality was low and the type of gene therapy did not account for differences in outcome. Study design characteristics accounted for a significant proportion of between-study heterogeneity. We observed similar findings in a data subset limited to the most common gene therapy.ConclusionAs the dysregulation of key molecular pathways is characteristic of gliomas, gene therapy remains a promising treatment for glioma. Nevertheless, we have identified areas for improvement in conduct and reporting of studies, and we provide a basis for sample size calculations. Further work should focus on genes of interest in paradigms recapitulating human disease. This might improve the translation of such therapies into the clinic.
Databáze: OpenAIRE
Externí odkaz: